Introduction: EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations relatively insensitive to first-and second-generation EGFR tyrosine kinase inhibitors (TKIs). However, recent early clinical data suggests these patients may benefit from newergeneration EGFR-TKIs. Comprehensive genomic profiling (CGP) identifies a broad spectrum of EGFRex20ins and associated co-occurring genomic alterations (GAs) present in NSCLC.
Introduction
EGFR exon 19 deletions and EGFR exon 21 L858R represent the vast majority of EGFR-activating mutations, and are exquisitely sensitive to approved EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. [1] [2] [3] Less common EGFR mutations have variable sensitivity to EGFR inhibitors, although many still show clinical sensitivity to EGFR TKIs (e.g., EGFR G719X, L861Q, and S768I). 4 EGFR exon 20 insertions (EGFRex20ins) are a collection of EGFR driver mutations characterized by inframe insertions that typically serve to constitutively upregulate EGFR kinase activity similar to sensitizing mutations (but are insensitive to first-and secondgeneration EGFR-TKIs). These alterations have previously been reported to comprise approximately 4% to 10% of all EGFR mutant lung cancers. [5] [6] [7] [8] The diverse array of exon 20 insertions and the challenges associated with identifying them may lead to underestimation of their true frequency. Although EGFRex20ins usually have the same transforming ability as more common EGFR-activating mutations and are thus considered driver mutations, they are typically unresponsive to first-and secondgeneration EGFR TKIs due to the modified structures of their kinase domains. [5] [6] [7] [8] Very few of these EGFRex20ins, such as A763_Y764insFQEA, have shown sensitivity to first-and second-generation EGFR TKIs. 9 Several next-generation EGFR TKIs (some with panhuman epidermal growth factor receptor activity) have shown pre-clinical activity against EGFRex20ins and are in clinical development (EGF816, AP32788, osimertinib, and poziotinib). 5, 10, 11 In particular, a strong signal of clinical activity was shown with poziotinib with an overall response rate of 64% in the first 11 patients in an early phase clinical trial. 12 However, no EGFR-TKIs are currently approved for EGFRex20ins and their diversity of structures suggests that different insertion events may have divergent responsiveness to various EGFR TKIs. Thus, identifying the full array and scope of EGFRex20ins is of paramount importance.
Studies examining EGFRex20ins have generally been limited to cases from single institutions. Certain nextgeneration sequencing approaches such as comprehensive genomic profiling (CGP) permit sequencing of the entire EGFR gene to broadly assess for diverse EGFRex20ins and co-existing genomic alterations (GAs) that may be relevant to the pathogenesis of EGFRex20ins-positive NSCLC. In addition to characterizing the clinical and pathologic characteristics of EGFRex20ins-positive NSCLC from a large dataset with molecular testing performed in the course of clinical care from multiple institutions, the purpose of this study was to assess the frequency and diversity of EGFRex20ins in NSCLC by their pattern of sequence alterations and co-occurring GAs, which may impact the development of targeted treatments for these patients.
Methods
DNA was extracted from 40-mm formalin-fixed paraffin-embedded sections. EGFRex20ins and cooccurring GAs were identified by hybrid capture-based CGP performed during the course of clinical care on 14,483 consecutive NSCLC specimens to a mean coverage depth of greater than 650X for 236 (version 1, July 2012 to August 2014) or 315 (version 2, August 2014 to June 2016) cancer-related genes plus selected introns from 19 or 28 genes frequently rearranged in cancer. EGFR amplification was defined as estimated copy number greater than 6 copies. 13 Clinical data such as age, sex, stage, and histologic subtype were abstracted from the accompanying pathology report submitted by the ordering physician. Treatment outcomes from these patients were included where available. Testing was performed in a Clinical Laboratory Improvement Amendments-certified, College of American Pathologists-accredited reference laboratory (Foundation Medicine, Inc., Cambridge, Massachusetts). Patient samples were evaluated for GAs, including base-pair substitutions, insertions/deletions (indels), copy number alterations, and rearrangements, as described previously. Tumor mutational burden (TMB) was characterized as the number of somatic base substitution or indel alterations per megabase (Mb) per previously described methods.
14 Approval for this study, including a waiver of informed consent and a Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the Western Institutional Review Board (Protocol No. 20152817).
Results
CGP performed on 14,483 NSCLC cases in the course of clinical care identified 2251 cases with EGFR mutations; 263 of these cases were EGFRex20ins, representing 12% of all EGFR-mutant NSCLC and 1.8% of all NSCLC cases tested. EGFRex20ins were the third most common type of EGFR mutation detected following EGFR exon 19 deletions (47%) and EGFR L858R (32%). Other less common EGFR mutations detected in this large case series include G719X (4%), L861Q (2%), S768I (1%), and cases with compound EGFR-activating mutations (2%) (Fig. 1) .
Clinical and pathologic characteristics were available for all of the 263 patients with EGFRex20ins as summarized in Table 1 . The large majority of cases EGFRex20ins were identified in lung adenocarcinoma (90%, 237 of 263), followed by NSCLC not otherwise specified (NOS) (9.1%, 24 of 263), and sarcomatoid histology (0.7%, 2 of 263). The median age for EGFRex20-positive cases was 63 years, and 62% of patients were female. Of the 263 patients with EGFRex20-ins-positive NSCLC, treatment outcomes were available for 11 patients. Five of those patients received either first-or second-generation EGFR TKIs, with none of the five patients showing a response to treatment and median time to progression of only 3.5 months (Supplementary Table 1 and RB transcriptional corepressor 1 (RB1) (11%) (Fig. 4) . Co-occurring alterations did not substantially differ between EGFRex20ins and canonical EGFR mutations (EGFR exon 19 deletion and EGFR L858R) that were negative for the most common acquired EGFR TKI resistance mutation, EGFR T790M ( (Table 2) .
Discussion
Herein we present the largest known dataset of EGFRex20ins NSCLC, wherein 64 unique EGFRex20ins sequence alterations are identified, reflecting the diversity of these EGFR driver mutations, which comprise 12% of EGFR-mutant NSCLC and 1.8% of all NSCLC in our series. With approximately 222,000 newly diagnosed lung cancer cases annually in the United States alone, this corresponds to approximately 3000 newly diagnosed EGFRex20ins cases per year in the United States.
15
EGFRex20ins were detected in 12% of EGFRmutant NSCLC cases, which is higher than previously reported in smaller single-institution series (w4% to 10% frequency). Prior records of molecular testing were not available for the majority of cases. Several reasons may explain the higher frequency of EGFRex20ins detected. This may reflect referral bias with enrichment for lung cancers from neversmoking patients. However, for other common EGFR alterations, frequencies detected were comparable to those reported in the literature (15.5% of all NSCLC cases). Thus, the higher frequency of EGFRex20ins is likely rather due to advancement of sequencing technology and improved detection of these alterations at lower mutant allele frequency by nextgeneration sequencing. Mutation-specific assays in some previous studies also likely underestimate the number of EGFRex20ins given the diversity of EGFRex20ins we detected by next-generation sequencing.
A previous study of 27 cases at a single institution described 13 unique EGFRex20ins variants. 6 The dataset herein reports 263 cases including 64 unique EGFRex20ins variants with concomitant molecular alterations and TMB, with a comparison of these cooccurring alterations to a large dataset of EGFR-WT and canonical EGFR-mutant NSCLC.
Sensitivity of the EGFR L858R and exon 19 deletions to EGFR TKIs is mediated by enhanced intrinsic affinity for EGFR TKI versus substrate adenosine triphosphate. Structural modeling and binding affinity studies of representative EGFRex20ins
showed that firstgeneration EGFR TKI binding affinity is similar to that of WT EGFR. 9 Identifying the spectrum of EGFRex20ins where next-generation EGFR TKI can fit into a sterically hindered EGFR exon 20 binding pocket is critical to showing anti-tumor activity and improving clinical outcomes in NSCLC patients harboring diverse EGFRex20ins.
9,15,16
The majority of EGFRex20ins were detected in lung adenocarcinoma, although they were also found in a limited number of lung cancers with sarcomatoid histology. In this retrospective series, these insertions were detected at a higher frequency than reported in smaller series suggesting that EGFRex20ins are more prevalent than previously reported. Although this dataset represents patients who were selected specifically by their physician to be tested for analysis, which may not represent a random cross-section of NSCLC, the higher frequency of EGFRex20ins reported could be due in part to comprehensive sequencing of EGFR compared to limitations of noncomprehensive assays performed in prior studies. Nevertheless, EGFRex20ins were the third most common EGFR-activating mutation following exon19del and L858R, and occur at approximately the same frequency as ROS1 gene fusions (w1% in our dataset; data not shown) and BRAF V600E mutations in NSCLC (w2% in our dataset; data not shown) where targeted therapies are approved with high rates of response and lengthy progression-free survival. Available treatment outcomes showed lack of response to first-and second-generation EGFR TKIs such as erlotinib, gefitinib, and afatinib, consistent with other series, and highlighting the need for new strategies to target EGFRex20ins. 19 The EGFR A763_Y764insFQEA insertion, for which sensitivity to first-and secondgeneration EGFR TKIs has been described, only comprised 6% of all EGFRex20ins in our series (thus representing less than 1% of all EGFR mutations). Although we detected more than 60 EGFRex20ins, the most frequently occurring (D770_N771>ASVDN, N771_P772>SVDNP, and N771_H773dupNPH) represent approximately 50% of all detected EGFRex20ins in this series (Fig. 3) . Studies of newer-generation EGFR TKIs showing pre-clinical and clinical efficacy against these particular EGFRex20ins would thus impact the greatest number of patients. More recently, poziotinib has shown robust pre-clinical and clinical activity; a confirmed response rate of 64% in EGFRex20ins NSCLC was noted in a phase 2 trial, albeit in a limited number of patients. 12 Poziotinib, due to its small size, can circumvent steric changes resulting from the exon 20 insertion to more effectively bind to mutant EGFR. Further understanding the spectrum of EGFRex20ins is important, as it is likely that among the 64 unique insertions we detected, there will be differential sensitivity to poziotinib and similar drugs due to the size and configuration of the drug-binding pocket based on the specific EGFRex20ins variant.
The most common genomic alterations co-occurring with EGFRex20ins were tumor suppressor (e.g., TP53 and RB1) and cell cycle alterations (e.g., CDKN2A/2B). These occurred at comparable frequency in NSCLCs samples with EGFR exon 19del and EGFR L585R without EGFR T790M (Table 2 , Fig. 4 ). Because EGFR T790M is the most common acquired resistance mutation to firstand second-generation EGFR TKIs, these were excluded for this comparison to control as best as possible for additional genomic aberrations resulting from acquired EGFR TKI resistance. As is typical of other oncogenic drivers, the vast majority of EGFRex20ins were mutually exclusive of other putative oncogenic drivers in NSCLC such as canonical EGFR, KRAS, BRAF, MET, and HER2 mutations, MET amplification, and ALK receptor tyrosine kinase (ALK), ROS1 and ret proto-oncogene (RET) fusions. EGFR amplification was detected in 22% of EGFRex20ins-positive NSCLCs, which is comparable to other EGFR mutations in our dataset when cases with cooccurring T790M are excluded (e.g., EGFR ex19del 23% and L858R 25%) and higher than EGFR-WT NSCLC (Fig. 4, Table 2 ), as noted in other studies in EGFR-mutant NSCLC. 20 Treatment with EGFR monoclonal antibodies based on EGFR amplification and overexpression has modestly improved clinical outcomes of squamous NSCLC, and cetuximab added to afatinib appears to increase response rates compared to afatinib alone in patients with EGFR exon 19 deletion or L858R. 21, 22 Small series have described activity of the addition of cetuximab to EGFR TKIs in EGFRex20ins NSCLC. 23, 24 Another important aspect of study is analysis of TMB, which has not been previously reported for EGFRex20ins. Immune checkpoint inhibition with programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) antibodies has revolutionized the treatment of NSCLC and improved survival outcomes for many lung cancer patients. 25 However, patients with EGFR-mutant NSCLC appear to derive less clinical benefit from PD-1/PD-L1 blockade and in a recent meta-analysis an overall survival benefit compared to chemotherapy was not shown. 26 In addition to PD-L1 expression, other features such as TMB appear to also be associated with clinical benefit to PD-1/PD-L1 antibodies, potentially relating to an increase in neoantigen specific T-cell activity. 27, 28 TMB measured by CGP is comparable to measurements by whole exome sequencing and is typically higher in smoking-associated lung cancer due to tobacco carcinogenesis.
14,29 Our study shows comparable TMB in EGFRex20ins cases to classic (exon 19 del or L858R) EGFR-mutant NSCLC that is lower than EGFR-WT NSCLC (Table 2) 
